GLP-1 receptor agonists have a 15+ year safety record in type 2 diabetes patients. Newer weight-loss approvals (Wegovy 2021, Zepbound 2023) extended the use case with similar safety findings in trials.
FDA boxed warning
All injectable GLP-1s carry a boxed warning for medullary thyroid carcinoma (MTC) based on rat studies. Human relevance is unclear, but personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2) is a contraindication.
Other notable risks
- Pancreatitis (rare, reversible if caught early)
- Gallbladder disease (rapid weight loss increases gallstone risk)
- Diabetic retinopathy progression (especially in patients with existing retinopathy)
- Suicidal ideation signal under FDA review (mixed evidence; see our GLP-1 mental health 2026 review)
When NOT to take GLP-1
- Personal or family history of MTC or MEN2
- Pregnancy or trying to conceive (2-month washout recommended)
- History of severe gastroparesis
Always discuss your individual risk profile with your prescriber.
Related resources
More in Side effects
What are the most common GLP-1 side effects?
Most side effects are gastrointestinal: nausea, constipation, diarrhea, and reflux. Typically peaks during dose escalation and improves with time.
How do I manage GLP-1 nausea?
Eat smaller meals, prioritize protein, avoid greasy or very sweet foods, and stay hydrated. Nausea typically improves after the first 4–8 weeks.